Indo Borax launches ₹150 crore open offer for Kronox Lab Sciences

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights
  • Indo Borax launches mandatory open offer for 25.79% stake in Kronox Lab Sciences
  • Offer price set at ₹157.27 per share, totaling maximum consideration of ₹150.5 crore
  • Acquirer secures 64.26% stake via separate share purchase agreement with promoters
  • Total financial arrangement includes ₹134.0 crore cash reserves and ₹25.0 crore PAC support
powered bylight_fuzz_icon
49470709

*this image is generated using AI for illustrative purposes only.

Indo Borax and Chemicals Limited has initiated a mandatory open offer to acquire a controlling stake in Kronox Lab Sciences . The acquirer aims to purchase up to 95,70,000 equity shares, representing 25.79% of the target’s voting share capital, at an offer price of ₹157.27 per share.

The transaction follows the execution of a share purchase agreement dated August 20, 2026, wherein Indo Borax agreed to acquire 64.26% of Kronox Lab Sciences from its existing promoters. Zenrock Chemicals Private Limited acts as a person acting in concert (PAC) with the acquirer. The total maximum consideration for the open offer stands at ₹150.5 crore, assuming full acceptance by public shareholders.

Offer Price and Valuation

The offer price of ₹157.27 per equity share was determined in accordance with SEBI (SAST) Regulations. It reflects the volume-weighted average market price of the shares on the National Stock Exchange over the 60 trading days preceding the public announcement. This price significantly exceeds the negotiated share purchase agreement price of ₹103.22 per share (₹105.87 inclusive of consultancy fees) paid to the selling promoters.

Financial Arrangements

Indo Borax has confirmed firm financial arrangements to meet the obligations under the open offer. The acquirer holds cash and cash equivalents of ₹134.0 crore as of August 19, 2026. Additionally, the PAC, Zenrock Chemicals, has committed ₹25.0 crore in financial support. A total escrow amount of ₹38.0 crore, representing 25.25% of the maximum consideration, has been deposited with Kotak Mahindra Bank Limited.

Target Company Profile

Kronox Lab Sciences manufactures high-purity specialty fine chemicals for pharmaceutical, nutraceutical, and biotech sectors. The company reported total income of ₹1,064.1 crore and profit after tax of ₹276.6 crore for FY26. For the quarter ended June 30, 2026, revenue stood at ₹296.8 crore with a net profit of ₹73.0 crore.

What the Numbers Show

The disparity between the negotiated promoter exit price and the public offer price highlights a significant value transfer to minority shareholders. While the promoters sold their stake at an effective price of ₹105.87 per share, public shareholders are being offered ₹157.27 per share. This premium of approximately 49% over the negotiated price underscores the regulatory requirement to protect minority interests in substantial acquisitions, potentially leading to immediate arbitrage opportunities if the market price remains below the offer price during the tendering period.

Historical Stock Returns for Kronox Lab Sciences

1 Day5 Days1 Month6 Months1 Year5 Years
-4.61%-3.54%+15.45%+49.87%+6.95%0.0%

How might the integration of Kronox Lab Sciences' specialty chemical portfolio affect Indo Borax's long-term revenue diversification and margin profile?

What impact will the ₹150.5 crore cash outflow and escrow deposits have on Indo Borax's liquidity position and future capital allocation strategies?

Could the significant premium offered to public shareholders trigger a broader wave of mandatory open offers in the Indian specialty chemicals sector?

Kronox Lab Sciences schedules 17th AGM for September 16, 2026

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • Kronox Lab Sciences schedules 17th AGM for September 16, 2026
  • Final dividend of ₹0.50 per share proposed for FY26
  • Reappointment of director Jogindersingh Jaswal on agenda
  • Cost auditor remuneration set at ₹90,000 p.a. for FY27
powered bylight_fuzz_icon
49135156

*this image is generated using AI for illustrative purposes only.

Kronox Lab Sciences has scheduled its 17th Annual General Meeting for September 16, 2026. The meeting will be held via video conferencing to transact ordinary and special business items.

The Board of Directors proposes a final dividend of ₹0.50 per equity share for the financial year ended March 31, 2026 (FY26). Shareholders will also consider the reappointment of Mr. Jogindersingh Jaswal as a director.

Key Agenda Items

The notice outlines specific resolutions for shareholder approval during the virtual meeting:

  • Adoption of the Audited Standalone Financial Statements for FY26.
  • Declaration of the final dividend.
  • Reappointment of Mr. Jogindersingh Jaswal, who retires by rotation.
  • Ratification of remuneration for Cost Auditors M/s. Diwanji & Associates.

Director Reappointment Details

Mr. Jogindersingh Jaswal seeks reappointment after serving since November 18, 2008. He holds a 26.39% stake in the company and draws an annual remuneration of ₹132 lakh. His expertise covers production, quality control, and human resources.

Cost Auditor Remuneration

The Board recommends ratifying the appointment of M/s. Diwanji & Associates as Cost Auditors for FY27. The proposed remuneration is fixed at ₹90,000 per annum plus applicable taxes. No directors or key managerial personnel have any financial interest in this resolution.

Meeting Logistics

The meeting will commence at 11:00 am on September 16, 2026. Remote e-voting will be available from September 13 to September 15, 2026. The cut-off date for voting rights is September 9, 2026. Share transfer books will remain closed from September 10 to September 16, 2026.

Historical Stock Returns for Kronox Lab Sciences

1 Day5 Days1 Month6 Months1 Year5 Years
-4.61%-3.54%+15.45%+49.87%+6.95%0.0%

How does the proposed ₹0.50 dividend per share compare to Kronox Lab Sciences' payout history, and what does this signal about the company's cash flow management for FY26?

What strategic initiatives or operational improvements is Mr. Jogindersingh Jaswal expected to drive during his renewed tenure given his extensive experience in production and quality control?

Will the adoption of the FY26 standalone financial statements reveal any significant changes in revenue growth or margin pressures compared to the previous fiscal year?

More News on Kronox Lab Sciences

1 Year Returns:+6.95%